While the breakneck pace of technological innovation has affected nearly every facet of modern life, the opportunities it has created in clinical research have been game-changing. This has been particularly…
Read More
At the recent Digital Biomarkers and Clinical Measures in Neurology meeting, Koneksa was honored to speak on the importance of digital biomarkers to research into central nervous system (CNS) conditions,…
Koneksa CMO John Wagner, MD, Ph.D. discussed the benefits and challenges of using biomarkers and translational science in clinical development programs at an FDA workshop hosted by the Duke-Margolis Center…
Koneksa’s unique expertise in designing, developing, and deploying digital health technology (DHT)-enabled biomarkers in clinical trials, and our experience analyzing the corresponding data, can provide value to your product’s journey….
This week, the American Society of Clinical Pharmacology and Therapeutics (ASCPT) held a two-day satellite session dedicated to discussing the challenges of conducting clinical trials in patient populations of limited…
“Standing on the shoulders of giants,” as Newton put it, is the foundation of science. That’s especially true in biomarker science, as we take decades of experience with laboratory biomarkers…
Multi-component biomarkers: what are they, and why does it matter? While they are increasingly common in medicine – especially in drug development – there are no “official” definitions yet of…
I was delighted to join several of my Koneksa colleagues in person at the recent 13th Summit for Clinical Ops Executives (SCOPE) conference in Orlando, Florida. The focus SCOPE has…
The Foundation for the National Institutes of Health (FNIH) is an organization that creates and leads alliances and public-private partnerships to support biomedical research, fighting disease in the United States…
It’s been a big year for Koneksa. We completed our Series B fundraising, securing $16 million to further investment in our industry-leading digital biomarker platform. We completed our work to…
